Zulvac 1+8 Bovis

RSS

Authorised

This medicine is authorised for use in the European Union

inactivated bluetongue virus, serotypes 1 and 8
MedicineVeterinaryAuthorised

Irish is available via eTranslation, the European Commission's machine translation service.

Translate to Irish | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

Up-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website

български (BG) (93.36 KB - PDF)

Amharc

español (ES) (81.97 KB - PDF)

Amharc

čeština (CS) (93.99 KB - PDF)

Amharc

dansk (DA) (83.34 KB - PDF)

Amharc

Deutsch (DE) (82.76 KB - PDF)

Amharc

eesti (ET) (82.18 KB - PDF)

Amharc

ελληνικά (EL) (93.76 KB - PDF)

Amharc

français (FR) (82.44 KB - PDF)

Amharc

Gaeilge (GA) (83.57 KB - PDF)

Amharc

hrvatski (HR) (92.27 KB - PDF)

Amharc

italiano (IT) (82.29 KB - PDF)

Amharc

latviešu (LV) (94.29 KB - PDF)

Amharc

lietuvių (LT) (94.03 KB - PDF)

Amharc

magyar (HU) (94.15 KB - PDF)

Amharc

Malti (MT) (95.95 KB - PDF)

Amharc

Nederlands (NL) (82.05 KB - PDF)

Amharc

polski (PL) (95.62 KB - PDF)

Amharc

português (PT) (83.01 KB - PDF)

Amharc

română (RO) (94.17 KB - PDF)

Amharc

slovenčina (SK) (94.08 KB - PDF)

Amharc

slovenščina (SL) (82.27 KB - PDF)

Amharc

suomi (FI) (81.54 KB - PDF)

Amharc

svenska (SV) (82.05 KB - PDF)

Amharc

Íslenska (IS) (83.29 KB - PDF)

Amharc

norsk (NO) (82 KB - PDF)

Amharc

Product information

български (BG) (91.78 KB - PDF)

Amharc

español (ES) (81.51 KB - PDF)

Amharc

čeština (CS) (92.48 KB - PDF)

Amharc

dansk (DA) (82.05 KB - PDF)

Amharc

Deutsch (DE) (81.72 KB - PDF)

Amharc

eesti (ET) (81.22 KB - PDF)

Amharc

ελληνικά (EL) (91.79 KB - PDF)

Amharc

français (FR) (81.63 KB - PDF)

Amharc

Gaeilge (GA) (81.36 KB - PDF)

Amharc

hrvatski (HR) (91.56 KB - PDF)

Amharc

italiano (IT) (81.76 KB - PDF)

Amharc

latviešu (LV) (92.14 KB - PDF)

Amharc

lietuvių (LT) (92.19 KB - PDF)

Amharc

magyar (HU) (92.76 KB - PDF)

Amharc

Malti (MT) (93.86 KB - PDF)

Amharc

Nederlands (NL) (81.15 KB - PDF)

Amharc

polski (PL) (93.22 KB - PDF)

Amharc

português (PT) (82.53 KB - PDF)

Amharc

română (RO) (91.73 KB - PDF)

Amharc

slovenčina (SK) (81.75 KB - PDF)

Amharc

slovenščina (SL) (81.76 KB - PDF)

Amharc

suomi (FI) (81.11 KB - PDF)

Amharc

svenska (SV) (81.47 KB - PDF)

Amharc

Íslenska (IS) (81.52 KB - PDF)

Amharc

norsk (NO) (81.52 KB - PDF)

Amharc

български (BG) (93.36 KB - PDF)

Amharc

español (ES) (81.97 KB - PDF)

Amharc

čeština (CS) (93.99 KB - PDF)

Amharc

dansk (DA) (83.34 KB - PDF)

Amharc

Deutsch (DE) (82.76 KB - PDF)

Amharc

eesti (ET) (82.18 KB - PDF)

Amharc

ελληνικά (EL) (93.76 KB - PDF)

Amharc

français (FR) (82.44 KB - PDF)

Amharc

Gaeilge (GA) (83.57 KB - PDF)

Amharc

hrvatski (HR) (92.27 KB - PDF)

Amharc

italiano (IT) (82.29 KB - PDF)

Amharc

latviešu (LV) (94.29 KB - PDF)

Amharc

lietuvių (LT) (94.03 KB - PDF)

Amharc

magyar (HU) (94.15 KB - PDF)

Amharc

Malti (MT) (95.95 KB - PDF)

Amharc

Nederlands (NL) (82.05 KB - PDF)

Amharc

polski (PL) (95.62 KB - PDF)

Amharc

português (PT) (83.01 KB - PDF)

Amharc

română (RO) (94.17 KB - PDF)

Amharc

slovenčina (SK) (94.08 KB - PDF)

Amharc

slovenščina (SL) (82.27 KB - PDF)

Amharc

suomi (FI) (81.54 KB - PDF)

Amharc

svenska (SV) (82.05 KB - PDF)

Amharc

Íslenska (IS) (83.29 KB - PDF)

Amharc

norsk (NO) (82 KB - PDF)

Amharc

Product details

Name of medicine
Zulvac 1+8 Bovis
Active substance
  • inactivated bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP
  • inactivated bluetongue virus, serotype 8, strain btv-8/bel2006/02
International non-proprietary name (INN) or common name
inactivated bluetongue virus, serotypes 1 and 8

Pharmacotherapeutic group

  • Immunologicals
  • Immunologicals for Bovidae
  • Cattle
  • Inactivated viral vaccines
  • bluetongue virus

Authorisation details

EMA product number
EMEA/V/C/002473

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see Accelerated assessment.

Assessment history

This page was last updated on

Share this page